cagrilintide novo nordisk can you take and tirzepatide together announced on February 23, 2026, that its Novo Nordisk takes a hit

Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)

Type I IGF receptors of Leydig cells are upregulated by hCG [PMID: 2962579] Laboratory literature summary: Type I IGF receptors of Leydig cells are upregulated by hCG

The real issue is what happens when that interest gets met by hype instead of clinical guidance

The key principle is identifying and managing any significant underlying pathology